🔎 Trials Near Me

Home › Soft Tissue Sarcoma › Texas › Houston

Soft Tissue Sarcoma clinical trials in Houston, TX

32 studies for Soft Tissue Sarcoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RecruitingPhase 1/2
  • Baylor College of Medicine, Houston
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

Anti-GD2 ADC M3554 in Advanced Solid Tumors

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06641908

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

RecruitingPhase 1/2
  • University Of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06797999

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

RecruitingPhase 1
  • UT MD Anderson Cancer Center, Houston
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

RecruitingPhase 1
  • UT MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05711615

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

RecruitingPhase 2
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • UT MD Anderson Cancer Center, Houston
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

Actinium Therapy for Late-stage Aggressive Sarcomas

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07156565

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06975293

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

RecruitingObservational study
  • M D Anderson Cancer Center, Houston
All ages · All sexes · Updated Aug 21, 2026 · NCT01772771

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

RecruitingPhase 2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07283731

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 12 and older · All sexes · Updated Aug 18, 2026 · NCT06474676

A Study of MGC026 in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting
  • M D Anderson Cancer Center, Houston
Ages 10 and older · All sexes · Updated Aug 11, 2026 · NCT04199026

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

RecruitingPhase 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
Ages 1 to 30 · All sexes · Updated Aug 6, 2026 · NCT07444619

IDOV-Immune for Advanced Solid Tumors

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

RecruitingObservational study
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT07377747

Lead-212 PSV359 Therapy for Patients With Solid Tumors

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT06710756

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

RecruitingPhase 1/2
  • UT MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06498648

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06789172

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT04771520

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

RecruitingPhase 2
  • M.D. Anderson Children's Cancer Hospital, Houston
Ages 8 to 30 · All sexes · Updated May 22, 2026 · NCT05726383

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

RecruitingPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT04969835

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Recruiting
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT04693377

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

RecruitingPhase 1
  • Texas Children's Hospital, Houston
Ages 1 to 25 · All sexes · Updated Jan 22, 2026 · NCT04995003

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521

BostonGene and Exigent Genomic INsight Study

RecruitingObservational study
  • Oncology Consultants, Houston
Ages 18 and older · All sexes · Updated Feb 17, 2025 · NCT06272864

About Soft Tissue Sarcoma

Soft tissue sarcoma refers to cancer that begins in the muscle, fat, vessels or tendons. It can cause a lump or swelling. See which treatments are available

More about Soft Tissue Sarcoma on MedlinePlus

Soft Tissue Sarcoma trials in other cities

Other studies in Houston

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.